Perrigo's OTC Core Could Expand To Include National Brands

Submitting an OTC switch of Nasonex would be a first for Perrigo, as would marketing a national brand OTC if the switch is approved. In tandem with announcing divesture of Perrigo's Rx business, CEO Uwe Rohrhoff says marketing national brands in some OTC categories fits in the company's "value-creation road map."

Perrigo Co. PLC isn't abandoning its tried-and-true focus on OTC drugs, but its strategic view is expanding from private label and store brand products to include a national brand in its first potential US Rx-to-OTC switch.

The Dublin-headquartered firm announced Aug. 9 that it has licensed exclusive US rights to develop and market an OTC version...